Virotherapy: The next addition to the standard of care for glioblastoma?

Marike L D Broekman; Lisa Nieland; Rob C Hoeben

doi:10.1016/j.ccell.2022.09.003

Virotherapy: The next addition to the standard of care for glioblastoma?

Cancer Cell. 2022 Oct 10;40(10):1089-1091. doi: 10.1016/j.ccell.2022.09.003. Epub 2022 Sep 29.

Authors

Marike L D Broekman¹, Lisa Nieland², Rob C Hoeben³

Affiliations

¹ Department of Neurosurgery, Leiden University Medical Center, 2300 RC Leiden, the Netherlands; Department of Neurosurgery, Haaglanden Medical Center, 2512 VA the Hague, the Netherlands; Department of Cell and Chemical Biology, Leiden University Medical Center, 2300 RC Leiden, the Netherlands. Electronic address: m.broekman@haaglandenmc.nl.
² Department of Neurosurgery, Leiden University Medical Center, 2300 RC Leiden, the Netherlands; Departments of Neurology and Radiology, Massachusetts General Hospital, and Neuroscience Program, Harvard Medical School, Boston, MA 02129, USA.
³ Department of Cell and Chemical Biology, Leiden University Medical Center, 2300 RC Leiden, the Netherlands.

PMID: 36179688
DOI: 10.1016/j.ccell.2022.09.003

Abstract

A recent Nature Medicine article reported a phase II single-arm trial assessing the efficacy of a triple-mutated, third-generation oncolytic herpes simplex virus type 1 in patients with recurrent or residual glioblastoma. We discuss the results and highlight the potential of locally administered virus-based therapies to fight these lethal tumors.

Publication types

Clinical Trial, Phase II

MeSH terms

Glioblastoma* / therapy
Herpesvirus 1, Human* / genetics
Humans
Oncolytic Virotherapy* / methods
Oncolytic Viruses* / genetics
Standard of Care